Literature DB >> 29105334

Genetic prognostication in uveal melanoma.

Mehmet Dogrusöz1, Martine J Jager1.   

Abstract

Uveal melanoma (UM) is a rare tumour with a high propensity to metastasize. Although no effective treatment for metastases yet exists, prognostication in UM is relevant for patient counselling, planning of follow-up and stratification in clinical trials. Besides conventional clinicopathologic characteristics, genetic tumour features with prognostic significance have been identified. Non-random chromosome aberrations such as monosomy 3 and gain of chromosome 8q are strongly correlated with metastatic risk, while gain of chromosome 6p indicates a low risk. Recently, mutations in genes such as BAP1, SF3B1 and EIF1AX have been shown to be related to patient outcome. Genetics of UM is a rapidly advancing field, which not only contributes to the understanding of the pathogenesis of this cancer, but also results in further refinement of prognostication. Concomitantly, advances have been made in the use of genetic tests. New methods for genetic typing of UM have been developed. Despite the considerable progress made recently, many questions remain, such as those relating to the reliability of prognostic genetic tests, and the use of biopsied or previously irradiated tumour tissue for prognostication by genetic testing. In this article, we review genetic prognostic indicators in UM, also comparing available genetic tests, addressing the clinical application of genetic prognostication and discussing future perspectives for improving genetic prognostication in UM.
© 2017 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  genetic testing; ocular melanoma; oncology; prognosis; survival; uveal melanoma

Mesh:

Substances:

Year:  2017        PMID: 29105334     DOI: 10.1111/aos.13580

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  25 in total

1.  Calpastatin participates in the regulation of cell migration in BAP1-deficient uveal melanoma cells.

Authors:  Han Yue; Feng-Xi Meng; Jiang Qian; Bin-Bin Xu; Gang Li; Ji-Hong Wu
Journal:  Int J Ophthalmol       Date:  2019-11-18       Impact factor: 1.779

Review 2.  Conjunctival Melanoma - Epidemiological Trends and Features.

Authors:  Snježana Kaštelan; Antonela Gverović Antunica; Lidija Beketić Orešković; Jasminka Salopek Rabatić; Boris Kasun; Ivana Bakija
Journal:  Pathol Oncol Res       Date:  2018-05-25       Impact factor: 3.201

3.  Comparison between patient-reported outcomes after enucleation and proton beam radiotherapy for uveal melanomas: a 2-year cohort study.

Authors:  Laura Hope-Stone; Stephen L Brown; Heinrich Heimann; Bertil Damato
Journal:  Eye (Lond)       Date:  2019-04-15       Impact factor: 3.775

Review 4.  Predictors of emotional distress in uveal melanoma survivors: a systematic review.

Authors:  Cari Davies; Stephen Lloyd Brown; Peter Fisher; Laura Hope-Stone; Debra Fisher; Andrew Morgan; Mary Gemma Cherry
Journal:  Eye (Lond)       Date:  2022-08-08       Impact factor: 4.456

Review 5.  Recent Advances and Challenges in Uveal Melanoma Immunotherapy.

Authors:  Yihang Fu; Wei Xiao; Yuxiang Mao
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

6.  Five Decades of Enucleations for Uveal Melanoma in One Center: More Tumors with High Risk Factors, No Improvement in Survival over Time.

Authors:  Christine D M Roelofsen; Annemijn P A Wierenga; Sjoerd van Duinen; Robert M Verdijk; Jaco Bleeker; Marina Marinkovic; Gregorius P M Luyten; Martine J Jager
Journal:  Ocul Oncol Pathol       Date:  2020-12-15

Review 7.  Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging-Part II: treatment indications and complications.

Authors:  Pietro Valerio Foti; Mario Travali; Renato Farina; Stefano Palmucci; Corrado Spatola; Rocco Luca Emanuele Liardo; Roberto Milazzotto; Luigi Raffaele; Vincenzo Salamone; Rosario Caltabiano; Giuseppe Broggi; Lidia Puzzo; Andrea Russo; Michele Reibaldi; Antonio Longo; Paolo Vigneri; Teresio Avitabile; Giovani Carlo Ettorre; Antonio Basile
Journal:  Insights Imaging       Date:  2021-06-04

Review 8.  Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging-Part I: MR imaging with pathologic correlation and technical considerations.

Authors:  Pietro Valerio Foti; Mario Travali; Renato Farina; Stefano Palmucci; Corrado Spatola; Luigi Raffaele; Vincenzo Salamone; Rosario Caltabiano; Giuseppe Broggi; Lidia Puzzo; Andrea Russo; Michele Reibaldi; Antonio Longo; Paolo Vigneri; Teresio Avitabile; Giovani Carlo Ettorre; Antonio Basile
Journal:  Insights Imaging       Date:  2021-06-03

9.  Aggressive uveal melanoma displays a high degree of centrosome amplification, opening the door to therapeutic intervention.

Authors:  Dorota Sabat-Pośpiech; Kim Fabian-Kolpanowicz; Helen Kalirai; Natalie Kipling; Sarah E Coupland; Judy M Coulson; Andrew B Fielding
Journal:  J Pathol Clin Res       Date:  2022-04-26

10.  Targeting HIF-activated collagen prolyl 4-hydroxylase expression disrupts collagen deposition and blocks primary and metastatic uveal melanoma growth.

Authors:  Stefan Kaluz; Qing Zhang; Yuki Kuranaga; Hua Yang; Satoru Osuka; Debanjan Bhattacharya; Narra S Devi; Jiyoung Mun; Wei Wang; Ruiwen Zhang; Mark M Goodman; Hans E Grossniklaus; Erwin G Van Meir
Journal:  Oncogene       Date:  2021-07-03       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.